1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

Search for publications

Only original articles, editorials, guidelines.

  • Romero Riquelme MA, Aspas Requena G, Lloret-Madrid P, Gil C, Aguiar E, Tormo M, Del Bernal Del Castillo T, Rodríguez Arbolí E, Serrano J, Sánchez-García J, Rodríguez-Medina C, Mariz JM, Ayala R, Martínez-López J, Amigo ML, Vives S, Algarra Algarra L, García Boyero R, Brioso J, Castaño T, Bergua Burgués JM, Salamero O, Bass Maturana MF, Colorado M, García Fortes M, Sayas Lloris MJ, Vicente BV, Chillón C, Pérez Santaolalla E, Madrigal MD, Labrador Gómez J, García Pérez MJ, Casado Calderón S, Pérez Encinas M, Balerdi Malcorra A, Rodríguez MS, Gómez García LM, Herrera Puente P, Arce Fernández O, Barrios García M, Noriega V, Fernández R, Mateos M, Lacalzada C, Almela Gallego Á, García Garay MC, Couto C, Pérez-Simón JA, Barragán González E, Montesinos P.

    Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

    AMERICAN JOURNAL OF HEMATOLOGY . 101(11): 2812-2826.

    [doi:10.1002/ajh.70488]

  • Jabbour E, Castagnetti F, Bardey-Kanaan M, Soichez R, Nguyen NT, Kelly D, Rizzo F, Patos P, García-Gutiérrez V.

    Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience.

    DRUG SAFETY . 49(11): 1525-1533.

    [doi:10.1007/s40264-026-01695-1]

  • Martin-Moro F, Muntanola Prat A, Gutierrez Lopez De Ocariz X, Vazquez Diaz MS, Morais L, Amarika I, Diez-Feijóo R, Bastos-Oreiro M, de la Cruz Benito B, Marco Ayala J, Ramos Cillan S, Jiménez-Ubieto A, Galindo-Navarro P, Correa JG, Lavilla Rubira E, García-Herce C, Moreno M, Domingo-Domenech E, Domínguez N, Alonso A, Otero MJ, Comai A, Bengochea Casado ML, Villegas C, Gutierrez NC, Lluch García R Sr, Fernández-Luis S, Soler JA, Cannata-Ortiz J, Medina Á, Martín-Consuegra S, Aceituno M, Villafuerte Gutierrez P, de Miguel Llorente D, Arguiñano JM, López-Marín J, Villalon L, Gulino H Sr, López-Guillermo A, Salar A.

    Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma.

    Blood Advances . 10(20): 7036-7047.

    [doi:10.1182/bloodadvances.2026020480]

  • Marquet-Palomanes J, Martin-Moro F, Garcia-Vela JA.

    Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape.

    Biomedicines . 14(10): .

    [doi:10.3390/biomedicines14102283]

  • Hernández-Boluda JC, Arellano-Rodrigo E, Pérez-Encinas M, Raya JM, Gómez-Casares MT, Ferrer-Marín F, Hernández-Sánchez A, Fox ML, Angona A, Cuevas B, Mata-Vázquez MI, Ayala R, de Las Heras N, Mora E, García-Gutiérrez V, Senín A, Villarreal J, Xicoy B, Pérez-López R, García-Fortes M, González de Villambrosia S, Magro E, Ramírez MJ, Gómez P, Ramírez-Payer A, Martínez-Valverde C, Pérez-Lamas L, García-Hernández C, Gasior M, Juárez-Salcedo LM, Ibáñez F, Antelo ML, Guerrero L, Alvarez-Larrán A, Pereira A.

    Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

    BRITISH JOURNAL OF HAEMATOLOGY . 209(4): 1715-1724.

    [doi:10.1111/bjh.70723]

  • Pérez-Martínez A, Cabrero M, Montoro J, Sánchez-Escamilla M, Cuesta MÁ, de Soria VG, González-Sierra P, Humala K, López-Godino O, Luna de Abia A, López-Corral L, Sanz J, Pascual MJ, Piñana JL, Bermúdez A, Bellón JM, Filaferro S, Orti G, Balsalobre P, Solano C.

    Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

    BONE MARROW TRANSPLANTATION . 61(10): 1335-1342.

    [doi:10.1038/s41409-026-02980-4]

  • Suarez-Trujillo F, Martínez PJ, Soleto I, Meijón M, Kerguelen A, Orts M, Planas A, Acedo N, Chacón-Calvo G, Garre A, Moreno-Lopez E, Butta N, Chaparro M, Baldán-Martín M, Gisbert JP.

    Tofacitinib does not affect platelet function or coagulation in patients with ulcerative colitis.

    Frontiers in Immunology . 17: 1941163-1941163.

    [doi:10.3389/fimmu.2026.1941163]

  • Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, Arnán M, Martínez Sánchez P, Herrera-Puente P, Serrano-López J, Rubio V, Marchante-Cepillo I, Cervera-Calvo M, Novo García A, Fernández Martín R, Gil Cortés C, Rodríguez-Medina C, Noriega-Concepción V, Alfonso-Piérola A, Loredo C, Antuña-Casal M, Boluda B, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Sánchez-García J, Bilbao C, Gómez-Casares MT, Martínez Cuadrón D, Montesinos P.

    Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

    AMERICAN JOURNAL OF HEMATOLOGY . 101(9): 2258-2268.

    [doi:10.1002/ajh.70424]

  • Carreño-Tarragona G, Gil-Manso R, Hernández-Boluda JC, Martínez-Ávila JC, Bellosillo B, Pérez-López R, Segura A, Ferrer-Marín F, Arellano-Rodrigo E, Angona A, García-Gutiérrez V, Noya MS, Blanco Á, Zamora L, Navarro M, Senín A, Magro E, Pastor-Galán I, Mata-Vázquez MI, Morales ML, Cuevas B, Vélez P, Mora E, Martínez-Bilbao C, Colmenares R, Alonso JM, Pérez-Encinas M, Caballero-Navarro G, Cortés MÁ, Santaliestra M, Raya JM, Blanco-Sánchez A, Hernández-Rivas JM, Martínez-López J, Ayala R, Álvarez-Larrán A.

    Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

    LEUKEMIA . 40(9): 1968-1976.

    [doi:10.1038/s41375-026-03035-9]

  • Filonenko K, Picardi M, Chauvie S, Filippi AR, Pirosa MC, Guerra L, Fallanca F, Bednarek M, Kurlapski M, Domingo-Domenech E, Visentin A, Patti C, García-Sanz R, Nunez J, Lopez-Jiménez J, Giza A, Wyszomirski A, Rambaldi A, Rossi D, Sureda A, Gallamini A, Zaucha JM.

    Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol.

    Biomedicines . 14(8): .

    [doi:10.3390/biomedicines14081861]

  • De Paz Arias R, Maortua Langdon G, Stuckey R, Giraldo P, Xicoy B, Martínez López J, Bautista G, Alonso Alonso JM, Noya MS, Sierra M, de Las Heras N, Pérez López R, Saavedra S, Gómez-García de Soria V, Chen-Liang TH, Santaliestra M, García Gutiérrez V.

    Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group.

    ANNALS OF HEMATOLOGY . 105(11): .

    [doi:10.1007/s00277-026-07039-4]

  • Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J.

    Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

    JOURNAL OF CLINICAL ONCOLOGY . 44(22): 2098-2109.

    [doi:10.1200/JCO-26-01080]

  • Barragán E, Gil JV, Ayala R, Chillón C, Soria E, Bilbao C, Larráyoz MJ, Prados de la Torre E, Solana A, Martínez-Cuadrón D, Rodríguez-Veiga R, Rodríguez-Arbolí E, Tormo M, Martínez P, Lavilla E, García-Garay MC, Arce O, Bergua J, Serrano J, Botella C, Lacalzada C, Almela-Gallego A, Lopez-Lorenzo JL, Valero M, Ibañez F, Foncillas MÁ, Rodriguez-Medina C, Olave M, Gómez-Correcha KG, Calderón MT, Bernal T, Labrador J, Oliva A, Madrigal MD, Hermosín L, Amador L, García-Belmonte D, Herrera P, Vives S, Perez-Encinas M, Algarra L, Casado S, Martínez-Chamorro C, Polo M, Balerdi A, Roldán A, Couto C, Pereiro M, Vanegas R, Llop M, Sargas C, Cionfrini A, Mendizábal Y, Sánchez J, Calasanz MJ, Gómez-Casares MT, Pérez-Simón JA, García-Sanz R, Martínez-López J, Montesinos P.

    Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

    Blood Neoplasia . 3(3): 100238-100238.

    [doi:10.1016/j.bneo.2026.100238]

  • Guerrero-Carreño X, Smits S, Esteban Lasso A, Samiotaki M, Calabuig-Navarro V, Iborra FJ, Rantanen F, Álvarez-Larrán A, Angona Figueras A, Bellosillo B, Sáez Marín AJ, García-Gutiérrez V, Dekkers DHW, Demmers JAA, Ferrer-Marín F, Hernández-Boluda JC, Matsakas A, Benavente Cuesta C, Vandenberghe P, Papadopoulos P.

    Platelet Proteome Links Metabolism to Reactivity in Essential Thrombocythemia.

    MOLECULAR & CELLULAR PROTEOMICS . 25(8): 101617-101617.

    [doi:10.1016/j.mcpro.2026.101617]

  • Villegas A, Ropero P, González FA, Morado M, Menor M, de la Iglesia S, López-Rubio M, Salido EJ, Abío M, Senent ML, Recasens V, Vagace JM, Fonte C, Hernández-Rivas JM, Raya JM, Ríos P, Peri VL, Herrera KA, Tenorio MC, Riso LL, Tena J, Molina MA, Vara M, Rodríguez I, Ricard P, Gómez M, Dusacovschi OP, Vidán JM, Groiss J, Ferre Ó, Orbe I, López RM, Ugalde N, Hidalgo MI, Hinojosa C, Rodríguez AI, Herrera E, Murúzabal MJ, Del Carmen Hernández M, Marco JE, Benavente C, de Eritropatología GE.

    Beta-Thalassemia in Spain: Results From the National Thalassemia Registry and Molecular Analysis of Patients With Transfusion-Dependent Thalassemia.

    JOURNAL OF CLINICAL LABORATORY ANALYSIS . 40(14): .

    [doi:10.1002/jcla.70272]

  • Martin-Moro F, Alcoceba M, Romero S, Marquet-Palomanes J, Alonso-Castronuño D, Astibia-Mahillo B, Andreu R, Perez-Alonso R, Rodriguez-Martin E, De Ramon C, Solano I, Martin Garcia-Sancho A, Piris-Villaespesa M, Blanco O, Roldan-Santiago E, Garcia-Marco JA, Subira D, Navarro-Bailon A, Garcia-Cosio M, Garcia-Vela JA, Lopez-Jimenez J.

    Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis.

    MODERN PATHOLOGY . 39(7): 101009-101009.

    [doi:10.1016/j.modpat.2026.101009]

  • Bailén R, Peña-Muñoz F, Bermúdez A, López-Corral L, Fox L, de Miguel C, Asensi P, Martín-González J, Pascual-Cascón MJ, Chinea A, González-Sierra P, Izquierdo I, Calbacho M, Vázquez J, Ceballos C, Morales-Curbelo A, Sánchez-Salinas A, Zanabili J, Sisinni L, González-Vicent M, Castilla L, Balsalobre P, Kwon M.

    Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy.

    Transplantation and Cellular Therapy . 32(7): .

    [doi:10.1016/j.jtct.2026.03.001]

  • Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E, Trigo F, Colorado M, Del Bernal Del Castillo T, Barragan E, Tormo M, Rodríguez Arbolí E, Serrano López J, García Boyero R, Castaño T, Herrera Puente P, Romero Riquelme MA, Sayas Lloris MJ, Algarra-Algarra L, Rodriguez-Medina C, Sossa Melo CL, Labrador Gomez J, Vives S, Salamero O, Amigo ML, Valero Nuñez M, Rojas C, Bass F, García-Fortes M, Vidriales Vicente B, Polo M, Benavente C, Madrigal MD, Espinoza M, Pérez-Encinas M, Amador Barciela ML, Bautista G, Solana-Altabella A, Cano-Ferri I, Colmenares R, García-Ramírez P, Ibáñez Alis F, Barrios García M, Rodríguez-Macías G, López M, Oliva Hernández AY, Cerveró CJ, Martínez-Cuadrón D, Chorão P, Bergua Burgues JM, Montesinos P.

    Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

    AMERICAN JOURNAL OF HEMATOLOGY . 101(7): 1692-1705.

    [doi:10.1002/ajh.70340]